August 12, 2014, Mumbai, India

GlaxoSmithKline Pharmaceuticals announces Q2 Results

The core Pharmaceuticals business grew by 3.7% for the quarter. The quarter continued to see the impact of the base effect of differential pricing cuts due to the Price Control Order, extending coverage to the National List of Essential Medicines (NLEM).

Commenting on the performance, Dr. Hasit B. Joshipura, Managing Director, said, “Growth has improved progressively across business verticals. During the quarter we continued to expand our Oncology portfolio with the launch of Vectibix™, which is the first Fully Human Monoclonal Antibody for the treatment of metastatic Colorectal Cancer (mCRC).”

About GlaxoSmithKline:
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world’s leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com.

For enquiries, please contact:
Nandini Goswami
General Manager, Corporate Communications
+91 22 24959203
nandini.x.goswami@gsk.com